Notice ID: 5f78d6157696481f91ef2d5ee5e63252Special Notice
Squibs for Fire Sprinkler Valves
Active, responses due . Full description on SAM.gov.
Description
THIS IS A NOTICE OF INTENT TO SOLE SOURCE, NOT A REQUEST FOR A QUOTE (RFQ). A SOLICITATION WILL NOT BE ISSUED AND QUOTES WILL NOT BE REQUESTED.
The Naval Surface Warfare Center Indian Head Division (NSWC IHD) intends to award a firm-fixed-price contract on a non-competitive basis to Cartridge Actuated Devices, Inc. (CAGE: 16148), located at 51 Dwight Pl, Fairfield, NJ 07004, for the acquisition of the following supply:
Item Description: Squibs for Fire Sprinkler Valves (Primer, Part Number: 074080-3)
Quantity: 50 Units
This action is being undertaken in accordance with FAR 13.106-1(b)(1) on the basis that Cartridge Actuated Devices, Inc. is the only known source capable of meeting the Government’s requirements, utilizing the simplified procedures for certain commercial items authorized under 41 U.S.C. 1901 (implemented by FAR Subpart 13.5).
The North American Industry Classification System (NAICS) code for this requirement is 325920 (Explosives Manufacturing), and the Federal Supply Code (FSC) is 1377 (Cartridge and Propellant Actuated Devices and Components).
This Notice of Intent is not a request for competitive proposals. However, interested parties may identify their interest and capability to respond to this requirement. All capability statements received by November 03, 2026, at 10:00 AM EST will be considered by the Government. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement.
Interested vendors must be registered in the System for Award Management (SAM) database at https://www.sam.gov prior to submission.
Responses must be submitted electronically via email to Shannon Wooten, Contract Specialist, at shannon.d.cloud-wooten.civ@us.navy.mil (or shannon.cloud-wooten@navy.mil) no later than 10:00 AM EST on November 03, 2026.
Overview
Agency:
Department of WarDepartment of the Navy
Office:NAVSEA.NAVSEA WARFARE CENTER.NSWC INDIAN HEAD DIVISION
Posted:October 20, 2026
NAICS:325920: Explosives Manufacturing
Last Updated:Oct 28, 2026
First published:
Last updated on SAM.gov:
PSC:1377: CARTRIDGE AND PROPELLANT ACTUATED DEVICES AND COMPONENTS
Set-Aside:Not specified
Type:Special Notice
Place of Performance:Indian Head, Maryland
Award Overview
Possible prior contracts
Sign in to see possible prior contracts for this requirement (matched by agency, NAICS and place of performance; not confirmed).
Contacts
Contracting Officer
Primary Contact
Shannon Wooten
Documents
No documents available.
Lifecycle
- 1Version 1Special NoticeCurrent
Squibs for Fire Sprinkler Valves
Similar Opportunities
Title | Phase | Agency | NAICS | Set Aside | Posted | Deadline | Location |
|---|---|---|---|---|---|---|---|
Award Notice for building 63 at Naval Surface Warfare Center Carderock Division (NSWCCD) at 9500 MacArthur Blvd, West Bethesda, MD 20817. | Awarded | 236220 | Total Small Business Set-Aside | 05/15/2026 | Open | - | |
| Pre-Solicitation | 811210 | No Set-Aside | 10/13/2026 | 10/23/2026 | Bethesda, MD | ||
This is a combined Sources Sought and Notice of Intent to Sole Source announcement. The U.S. Army Contracting Command – Aberdeen Proving Ground (ACC-APG), on behalf of the Headquarters, Department of the Army (HQDA) G-2, intends to award three separate Firm-Fixed-Price (FFP) sole-source contracts to support the interim transition of legacy Contractor Owned, Contractor Operated (COCO) airborne Intelligence, Surveillance, and Reconnaissance (ISR) platforms to a Government Owned, Government Operated (GOGO) model. This notice is published for market research purposes to identify any other parties that may be capable of satisfying the Government’s requirement and to provide a synopsis of the proposed contract actions. The Government intends to solicit and negotiate with only the following Original Equipment Manufacturers (OEMs) under the authority of Federal Acquisition Regulation (FAR) 6.302-1, "Only one responsible source and no other supplies or services will satisfy agency requirements." Intended Source 1: Sierra Nevada Corporation (SNC): 2 Aircraft "ATHENA S" Intended Source 2: L3 Technologies (now L3Harris Technologies, Inc.): 1 Aircraft "ARES" Intended Source 3: MAG Aerospace: 2 Aircraft "ATHENA R" HQDA G-2 requires uninterrupted access to highly specialized airborne ISR platforms, integrated mission equipment (SIGINT, sensors, datalinks), and cleared personnel to ensure a seamless transition of legacy capabilities to the High Accuracy Detection and Exploitation System (HADES) Program of Record. HQDA G-2 concluded that Sierra Nevada Corporation (SNC), L3 Technologies, and MAG Aerospace are the only sources capable of meeting the Government’s requirement without a substantial duplication of cost and unacceptable delays in fulfilling the requirement. The justification is based on the following: Unique OEM Status and Proprietary Data: The intended vendors are the OEMs of the proprietary aircraft, possess integrated mission systems, and hold active Army Airworthiness Releases (AWRs) for these specific platforms. Avoidance of Substantial Duplication of Cost: Awarding this requirement to any other source would require the Government to incur hundreds of millions of dollars in non-recurring engineering (NRE) costs to acquire, modify, and certify a duplicate fleet of legacy aircraft. Prevention of Unacceptable Delays: Only the incumbent OEMs can guarantee that the capability is in place by award deadline. A competitive action would introduce a multi-year lead time for aircraft acquisition and integration, resulting in a catastrophic operational gap. Cleared Personnel and Facilities: The intended sources currently employ the required workforce of which approximately 85% possess active Top Secret/Sensitive Compartmented Information (TS/SCI) clearances and have access to the necessary secure facilities (SCIFs). While the Government intends to proceed with a sole-source award, all responsible sources are invited to submit a capability statement demonstrating their ability to meet the requirements outlined above. Interested parties who believe they are fully capable of meeting this requirement must submit a capability statement that provides clear and convincing evidence of their ability to perform this work without incurring the substantial duplication of cost or unacceptable delays described herein. Page limit: (5) five. The capability statement must include, at a minimum: Company name, address, UEI, CAGE code, and business size status. Approach demonstrating how the contractor can provide the required modified aircraft, integrated mission systems, and obtain Army Airworthiness Releases to meet a November 2027 deadline. A narrative explaining how the contractor can fulfill this requirement without the Government incurring substantial NRE and duplicate acquisition costs. Evidence of an available workforce possessing the requisite TS/SCI clearances and access to required secure facilities. | Market Research | 541990 | No Set-Aside | 10/06/2026 | 10/16/2026 | - | |
THIS IS A REQUEST FOR INFORMATION (RFI) ONLY In accordance with RFO 15.101(c), this RFI is issued solely for information and planning purposes. It does not constitute a solicitation for proposals, quotations, or abstracts, nor does it obligate the Government to award a contract or pay for any information provided. Responses will not be returned. No reimbursement will be made for costs associated with responding to this notice. 1. Background Research supported and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (HHS), strives to understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases that threaten millions of human lives. The NIAID Division of Microbiology and Infectious Diseases (DMID) supports extramural research to control and prevent diseases caused by virtually all infectious agents, an essential component of U.S. efforts to ensure the health and safety of the American people. Through multiple grant- and contract-funded research programs, NIAID supports a broad range of clinical research, including single-site and multi-center trials spanning Phase 0-4 therapeutics and vaccines, new vaccine formulations, schedules, and modes of delivery; surveillance or natural history / cohort studies for pathogens of interest; evaluation of novel diagnostics; and clinical trials designed to find additional uses for already approved therapies for selected infectious diseases. The portfolio includes primarily domestic clinical sites, with the ability to support international studies. As part of clinical research portfolio, NIAID has regulatory obligations for clinical trials that include standardized deliverables, reporting, safety oversight, and monitoring. NIAID therefore requires resources to support its clinical research activities in compliance with regulatory requirements. One of those resources is a Statistical and Data Coordinating Center (SDCC) which provides centralized data management, statistical, and specimen tracking services essential to this clinical research portfolio. NIAID is exploring the re-competition of its Statistical and Data Coordinating Center (SDCC) for Clinical Research in Infectious Diseases (CRID) contract. 2. Purpose The Government is issuing this RFI to: Facilitate early engagement with industry prior to release of a formal Request for Proposals (RFP), in accordance with RFO 15.101(c). Assess current market capabilities and vendor offerings relevant to SDCC services. Gather input on industry best practices to inform development of a future Statement of Work (SOW). Support fair and open competition in accordance with FAR 5.401. 3. Summary of Anticipated Scope and Targeted Feedback The anticipated SDCC contract encompasses the following broad functional areas. Respondents are encouraged to provide specific feedback on each area, including comments on feasibility, gaps, ambiguities, industry best practices, and any suggested refinements. 3.1 Overall Questions Targeted feedback requested: To what extent can or should Artificial Intelligence (AI) tools or platforms be incorporated into the SOW while maintaining confidentially of participant data? 3.2 Data Collection and Management The contractor will operate and maintain a state-of-the-art, 21 CFR Part 11-compliant clinical data system supporting data collection, automated data transfer, validation, storage, and submission to the FDA, from a large portfolio of domestic clinical sites, with the ability to support international studies. Targeted feedback requested: What commercial or proprietary platforms are best suited to support a portfolio of this scale and diversity while also meeting the standards of government-funded computer systems and Food and Drug Administration (FDA) regulatory submissions? What are their strengths and limitations in: an international setting; multi-site protocols; multi-protocol environments; and data collection methods from multiple sources, including electronic health records (EHR), electronic source, and paper source? How should the Statement of Work (SOW) address data system transition and continuity of operations at contract start-up to minimize disruption to ongoing studies? 3.3 Data Quality Assurance and Control The contractor shall provide and maintain a quality control system for monitoring the accuracy, completeness, and timeliness of the data, by study sites at each stage of a study, beginning with study initiation/participant enrollment and proceeding to the generation of final data sets. The system shall provide for verification of 100 percent of study data for audit readiness. Targeted feedback requested: What contractor involvement with development of data standards (i.e., via CDISC working groups and committees) should the SOW require to ensure innovation and continuous improvement in how data are collected? As CDISC and other standards continue to evolve, what mechanisms should the SOW require to ensure ongoing compliance without cost or schedule impact to the Government? 3.4 Protocol and Other Study-Related Materials The contractor shall provide services in the preparation, writing, review, revision, and distribution of protocol-related documents and materials (i.e., Manual of Procedures (MOP)) in collaboration with the study team and in support of implementation of the clinical protocol. Targeted feedback requested: What are industry standard timelines for development of clinical protocols and other study related materials, and what should the SOW require for their delivery schedule? What are industry standard timelines for the development of study data system(s), what best practices are recommended to facilitate rapid development of the data system, and what should the SOW require for the delivery schedule? 3.5 Communication, Collaboration, and Reporting The Contractor shall coordinate and collaborate with NIAID and other NIAID Clinical Research Infrastructure contractors and grant recipients to facilitate study implementation and assess study progress. The Contractor shall operate and maintain a web-based resource to share clinical research information and study materials with the NIAID, the study team, and participating study sites. Targeted feedback requested: What should the SOW require to ensure productive collaborations with multiple other contractors and grant recipients? What are industry standards for resources and platforms that can be used to share clinical research information at fixed costs to the Government? 3.6 Statistical Design and Analysis The Contractor shall provide expertise, advice, and assistance in the development of statistical designs of clinical concepts, statistical analysis plans, and in preparation of interim and final analyses for clinical research activities. Targeted feedback requested: What emerging statistical methodologies (e.g., adaptive trial designs, Bayesian approaches) should the SOW explicitly accommodate, and how should the Government structure tasking to access these capabilities efficiently? What should the SOW require for approaches or platforms for statistical analysis that encompass: standard clinical trial analysis, broad range of –Omics datasets, and generation of publication-ready tables and figures. 3.7 Clinical Site Training and Technical Assistance The Contractor shall train clinical site personnel on data systems and procedures, maintain a 24/7 help desk accessible from domestic and international locations, and assess site capabilities for studies not using SDCC systems. Targeted feedback requested: What are the most significant challenges in supporting clinical sites with respect to data system access, connectivity, and training, and how should the SOW account for them? 3.8 Electronic Specimen Tracking The Contractor shall provide and maintain an electronic specimen tracking system, for use by the SDCC, study sites, laboratories, and NIAID, to track study specimens in real time. Targeted feedback requested: Are there commercially available specimen tracking platforms that integrate natively with clinical data management systems, and should the SOW require such integration or permit modular solutions? 3.9 Data Storage The contractor shall maintain a secure and validated data storage system for clinical research and clinical trial data and analyses from current and future trials. Targeted feedback requested: What should the SOW include as requirements for data storage that allow for occasional data access for analysis while limiting cost to the Government? What should the SOW require for the maintenance of data from completed studies, such that results and performance metrics can be readily accessed from across all studies? 3.10 Data Sharing The contractor shall distribute, transfer, and/or share data and metadata to NIH and NIAID-designated repositories following completion of the clinical trial while ensuring data are appropriately and commensurately de-identified. Targeted feedback requested: What should the SOW require for methods and procedures to reliably de-identify clinical trial data? 3.11 Project Management The contractor shall provide for the overall management, integration and coordination of all contract activities, including the management and coordination of activities carried out under subcontracts if applicable Targeted feedback requested: What are critical elements of program and project management necessary to operate a resource to provide centralized data management and statistical services essential to support a wide variety of clinical research activities across multiple infectious disease programs involving domestic and international sites? 4. Requested Vendor Information In addition to SOW feedback above, respondents are asked to provide: Organizational Overview: Company name, address, UEI number, applicable NAICS code(s), and business size designation. Relevant Experience: Summary of prior or current experience managing SDCC or comparable data coordinating center functions, including scale (number of studies/sites) and therapeutic areas supported. Technical Capabilities: Description of systems, infrastructure, and personnel available to support the functional areas described above. International Experience: Demonstrated capability to support clinical trials at sites outside the United States. Teaming and Subcontracting: Whether your organization anticipates teaming agreements, or subcontracting, and in what functional areas. 5. Submission Instructions Responses should be limited to ten (10) pages or fewer, excluding cover page and organizational information. Submissions must be in PDF format and sent electronically to: Point of Contact: Miranda Adams, Contracting Officer Email: miranda.adams@nih.gov Responses are due no later than July 8, 2026, at 5:00 p.m. EDT. Telephone responses will not be accepted. The Government reserves the right to use any non-proprietary information received for acquisition planning purposes. Confidentiality No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s). All submissions become Government property and will not be returned. Disclaimer This RFI is issued solely for information and planning purposes to facilitate the acquisition planning process. It does not constitute a Request for Proposal (RFP) or a promise to issue an RFP in the future, nor does it restrict the Government as to the ultimate acquisition approach. This notice does NOT obligate the Government to award a contract or otherwise pay for the information provided in response. Further, NIAID is not seeking proposals through this RFI and will not accept unsolicited proposals. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Information provided will be used to assess tradeoffs and alternatives available for the potential requirement and may lead to the development of a solicitation. Any contract that might be awarded based on information received or derived from this RFI will be the outcome of a competitive process. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback with respect to any information submitted. Potential respondents should continue to monitor SAM.gov for any follow-on solicitation or additional information related to this requirement. | Market Research | 541713 | No Set-Aside | 06/11/2026 | 07/08/2026 | - | |
THIS IS A REQUEST FOR INFORMATION (RFI) ONLY In accordance with RFO 15.101(c), this RFI is issued solely for information and planning purposes. It does not constitute a solicitation for proposals, quotations, or abstracts, nor does it obligate the Government to award a contract or pay for any information provided. Responses will not be returned. No reimbursement will be made for costs associated with responding to this notice. 1. Background Research supported and conducted by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Department of Health and Human Services (HHS), strives to understand, treat, and ultimately prevent infectious, immunologic, and allergic diseases that threaten millions of human lives. The NIAID Division of Microbiology and Infectious Diseases (DMID) supports extramural research to control and prevent diseases caused by virtually all infectious agents, an essential component of U.S. efforts to ensure the health and safety of the American people. Through multiple grant- and contract-funded research programs, NIAID supports a broad range of clinical research, including single-site and multi-center trials spanning Phase 0-4 therapeutics and vaccines, new vaccine formulations, schedules, and modes of delivery; surveillance or natural history / cohort studies for pathogens of interest; evaluation of novel diagnostics; and clinical trials designed to find additional uses for already approved therapies for selected infectious diseases. The portfolio includes primarily domestic clinical sites, with the ability to support international studies. As part of clinical research portfolio, NIAID has regulatory obligations for clinical trials that include standardized deliverables, reporting, safety oversight, and monitoring. NIAID therefore requires resources to support its clinical research activities in compliance with regulatory requirements. One of those resources is a Statistical and Data Coordinating Center (SDCC) which provides centralized data management, statistical, and specimen tracking services essential to this clinical research portfolio. NIAID is exploring the re-competition of its Statistical and Data Coordinating Center (SDCC) for Clinical Research in Infectious Diseases (CRID) contract. 2. Purpose The Government is issuing this RFI to: Facilitate early engagement with industry prior to release of a formal Request for Proposals (RFP), in accordance with RFO 15.101(c). Assess current market capabilities and vendor offerings relevant to SDCC services. Gather input on industry best practices to inform development of a future Statement of Work (SOW). Support fair and open competition in accordance with FAR 5.401. 3. Summary of Anticipated Scope and Targeted Feedback The anticipated SDCC contract encompasses the following broad functional areas. Respondents are encouraged to provide specific feedback on each area, including comments on feasibility, gaps, ambiguities, industry best practices, and any suggested refinements. 3.1 Overall Questions Targeted feedback requested: To what extent can or should Artificial Intelligence (AI) tools or platforms be incorporated into the SOW while maintaining confidentially of participant data? 3.2 Data Collection and Management The contractor will operate and maintain a state-of-the-art, 21 CFR Part 11-compliant clinical data system supporting data collection, automated data transfer, validation, storage, and submission to the FDA, from a large portfolio of domestic clinical sites, with the ability to support international studies. Targeted feedback requested: What commercial or proprietary platforms are best suited to support a portfolio of this scale and diversity while also meeting the standards of government-funded computer systems and Food and Drug Administration (FDA) regulatory submissions? What are their strengths and limitations in: an international setting; multi-site protocols; multi-protocol environments; and data collection methods from multiple sources, including electronic health records (EHR), electronic source, and paper source? How should the Statement of Work (SOW) address data system transition and continuity of operations at contract start-up to minimize disruption to ongoing studies? 3.3 Data Quality Assurance and Control The contractor shall provide and maintain a quality control system for monitoring the accuracy, completeness, and timeliness of the data, by study sites at each stage of a study, beginning with study initiation/participant enrollment and proceeding to the generation of final data sets. The system shall provide for verification of 100 percent of study data for audit readiness. Targeted feedback requested: What contractor involvement with development of data standards (i.e., via CDISC working groups and committees) should the SOW require to ensure innovation and continuous improvement in how data are collected? As CDISC and other standards continue to evolve, what mechanisms should the SOW require to ensure ongoing compliance without cost or schedule impact to the Government? 3.4 Protocol and Other Study-Related Materials The contractor shall provide services in the preparation, writing, review, revision, and distribution of protocol-related documents and materials (i.e., Manual of Procedures (MOP)) in collaboration with the study team and in support of implementation of the clinical protocol. Targeted feedback requested: What are industry standard timelines for development of clinical protocols and other study related materials, and what should the SOW require for their delivery schedule? What are industry standard timelines for the development of study data system(s), what best practices are recommended to facilitate rapid development of the data system, and what should the SOW require for the delivery schedule? 3.5 Communication, Collaboration, and Reporting The Contractor shall coordinate and collaborate with NIAID and other NIAID Clinical Research Infrastructure contractors and grant recipients to facilitate study implementation and assess study progress. The Contractor shall operate and maintain a web-based resource to share clinical research information and study materials with the NIAID, the study team, and participating study sites. Targeted feedback requested: What should the SOW require to ensure productive collaborations with multiple other contractors and grant recipients? What are industry standards for resources and platforms that can be used to share clinical research information at fixed costs to the Government? 3.6 Statistical Design and Analysis The Contractor shall provide expertise, advice, and assistance in the development of statistical designs of clinical concepts, statistical analysis plans, and in preparation of interim and final analyses for clinical research activities. Targeted feedback requested: What emerging statistical methodologies (e.g., adaptive trial designs, Bayesian approaches) should the SOW explicitly accommodate, and how should the Government structure tasking to access these capabilities efficiently? What should the SOW require for approaches or platforms for statistical analysis that encompass: standard clinical trial analysis, broad range of –Omics datasets, and generation of publication-ready tables and figures. 3.7 Clinical Site Training and Technical Assistance The Contractor shall train clinical site personnel on data systems and procedures, maintain a 24/7 help desk accessible from domestic and international locations, and assess site capabilities for studies not using SDCC systems. Targeted feedback requested: What are the most significant challenges in supporting clinical sites with respect to data system access, connectivity, and training, and how should the SOW account for them? 3.8 Electronic Specimen Tracking The Contractor shall provide and maintain an electronic specimen tracking system, for use by the SDCC, study sites, laboratories, and NIAID, to track study specimens in real time. Targeted feedback requested: Are there commercially available specimen tracking platforms that integrate natively with clinical data management systems, and should the SOW require such integration or permit modular solutions? 3.9 Data Storage The contractor shall maintain a secure and validated data storage system for clinical research and clinical trial data and analyses from current and future trials. Targeted feedback requested: What should the SOW include as requirements for data storage that allow for occasional data access for analysis while limiting cost to the Government? What should the SOW require for the maintenance of data from completed studies, such that results and performance metrics can be readily accessed from across all studies? 3.10 Data Sharing The contractor shall distribute, transfer, and/or share data and metadata to NIH and NIAID-designated repositories following completion of the clinical trial while ensuring data are appropriately and commensurately de-identified. Targeted feedback requested: What should the SOW require for methods and procedures to reliably de-identify clinical trial data? 3.11 Project Management The contractor shall provide for the overall management, integration and coordination of all contract activities, including the management and coordination of activities carried out under subcontracts if applicable Targeted feedback requested: What are critical elements of program and project management necessary to operate a resource to provide centralized data management and statistical services essential to support a wide variety of clinical research activities across multiple infectious disease programs involving domestic and international sites? 4. Requested Vendor Information In addition to SOW feedback above, respondents are asked to provide: Organizational Overview: Company name, address, UEI number, applicable NAICS code(s), and business size designation. Relevant Experience: Summary of prior or current experience managing SDCC or comparable data coordinating center functions, including scale (number of studies/sites) and therapeutic areas supported. Technical Capabilities: Description of systems, infrastructure, and personnel available to support the functional areas described above. International Experience: Demonstrated capability to support clinical trials at sites outside the United States. Teaming and Subcontracting: Whether your organization anticipates teaming agreements, or subcontracting, and in what functional areas. 5. Submission Instructions Responses should be limited to ten (10) pages or fewer, excluding cover page and organizational information. Submissions must be in PDF format and sent electronically to: Point of Contact: Miranda Adams, Contracting Officer Email: miranda.adams@nih.gov Responses are due no later than July 8, 2026, at 5:00 p.m. EDT. Telephone responses will not be accepted. The Government reserves the right to use any non-proprietary information received for acquisition planning purposes. Confidentiality No proprietary, classified, confidential, or sensitive information should be included in your response. The Government reserves the right to use any non-proprietary technical information in any resultant solicitation(s). All submissions become Government property and will not be returned. Disclaimer This RFI is issued solely for information and planning purposes to facilitate the acquisition planning process. It does not constitute a Request for Proposal (RFP) or a promise to issue an RFP in the future, nor does it restrict the Government as to the ultimate acquisition approach. This notice does NOT obligate the Government to award a contract or otherwise pay for the information provided in response. Further, NIAID is not seeking proposals through this RFI and will not accept unsolicited proposals. The Government reserves the right to use information provided by respondents for any purpose deemed necessary and legally appropriate. Information provided will be used to assess tradeoffs and alternatives available for the potential requirement and may lead to the development of a solicitation. Any contract that might be awarded based on information received or derived from this RFI will be the outcome of a competitive process. Respondents are advised that the Government is under no obligation to acknowledge receipt of the information received or provide feedback with respect to any information submitted. Potential respondents should continue to monitor SAM.gov for any follow-on solicitation or additional information related to this requirement. | Market Research | 541714 | No Set-Aside | 06/10/2026 | 07/08/2026 | - |
Additional Details
Solicitation Number
N00174-27-SIMACQ-102-0051
Archive Date
Nov 18, 2026
Office Address
INDIAN HEAD, MD, 20640-1533